|
|
Volumn 15, Issue 2, 2019, Pages 106-107
|
|
Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: ASCO clinical practice guideline focused update
a
c
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BREAST CANCER;
CANCER HORMONE THERAPY;
CANCER STAGING;
CLINICAL PRACTICE;
FEMALE;
GENERAL PRACTITIONER;
HUMAN;
ONCOLOGY NURSE;
PHYSICIAN ASSISTANT;
POSTMENOPAUSE;
PRACTICE GUIDELINE;
RADIATION ONCOLOGIST;
REVIEW;
ADJUVANT CHEMOTHERAPY;
BREAST TUMOR;
DISEASE MANAGEMENT;
METABOLISM;
MORTALITY;
TREATMENT OUTCOME;
ANTINEOPLASTIC AGENT;
ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
ERBB2 PROTEIN, HUMAN;
ESTROGEN RECEPTOR;
PROGESTERONE RECEPTOR;
TUMOR MARKER;
ANTINEOPLASTIC AGENTS, HORMONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BIOMARKERS, TUMOR;
BREAST NEOPLASMS;
CHEMOTHERAPY, ADJUVANT;
DISEASE MANAGEMENT;
FEMALE;
HUMANS;
RECEPTOR, ERBB-2;
RECEPTORS, ESTROGEN;
RECEPTORS, PROGESTERONE;
TREATMENT OUTCOME;
|
|
EID: 85061562329
PISSN: 15547477
EISSN: 1935469X
Source Type: Journal
DOI: 10.1200/JOP.18.00617 Document Type: Review |
|
Times cited : (36)
|
|
References (4)
|
